{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:03:32Z","timestamp":1782965012658,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00228-019-02725-x","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T08:03:41Z","timestamp":1564992221000},"page":"1555-1563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-6275","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Barrail-Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Goldwirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Gel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Laforest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Lavenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Danjou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Radenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Houssel-Debry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Duvoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"De Ledinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Canva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"D\u2019Alteroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Botta-Fridlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Cagnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Fougerou-Leurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges-Philippe","family":"Pageaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Duclos-Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Taburet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Coilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"issue":"32","key":"2725_CR1","doi-asserted-by":"publisher","first-page":"9526","DOI":"10.3748\/wjg.v21.i32.9526","volume":"21","author":"E Cholongitas","year":"2015","unstructured":"Cholongitas E, Pipili C, Papatheodoridis G (2015) Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World J Gastroenterol WJG 21(32):9526\u20139533","journal-title":"World J Gastroenterol WJG"},{"issue":"4","key":"2725_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jhep.2016.05.039","volume":"65","author":"Audrey Coilly","year":"2016","unstructured":"Coilly A, Fougerou-Leurent C, de Ledinghen V, et al. (2016) Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - the ANRS CUPILT study. J Hepatol 65(4):711\u2013718","journal-title":"Journal of Hepatology"},{"issue":"6","key":"2725_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/tid.12606","volume":"18","author":"Nathanael Raschzok","year":"2016","unstructured":"Raschzok N, Schott E, Reutzel-Selke A, et al. (2016) The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C. Transpl Infect Dis.:n\/a-n\/a 18(6):896\u2013903","journal-title":"Transplant Infectious Disease"},{"issue":"11","key":"2725_CR4","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","volume":"65","author":"TM Welzel","year":"2016","unstructured":"Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S (2016) Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 65(11):1861\u20131870","journal-title":"Gut."},{"issue":"3","key":"2725_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijantimicag.2016.12.004","volume":"49","author":"EJ Smolders","year":"2017","unstructured":"Smolders EJ, Pape S, de Kanter CTMM, van den Berg AP, Drenth JPH, Burger DM (2017) Decreased tacrolimus plasma concentrations during HCV therapy: a drug\u2013drug interaction or is there an alternative explanation? Int J Antimicrob Agents 49(3):379\u2013382","journal-title":"Int J Antimicrob Agents"},{"key":"2725_CR6","unstructured":"Liu H-Y, Cheung CYS, Cooper SE (2018) Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis. BMJ Case Rep. :bcr-2017\u2013222477"},{"issue":"2","key":"2725_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/bcp.13095","volume":"83","author":"Sarah Talavera Pons","year":"2016","unstructured":"Talavera Pons S, Boyer A, Lamblin G, et al. (2017) Managing drug\u2013drug interactions with new direct-acting antiviral agents in chronic hepatitis C. Br J Clin Pharmacol :n\/a-n\/a 83(2):269\u2013293","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"2725_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"T Vanhove","year":"2016","unstructured":"Vanhove T, Annaert P, Kuypers DRJ (2016) Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 48(1):88\u2013112","journal-title":"Drug Metab Rev"},{"issue":"2","key":"2725_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","volume":"29","author":"N Shuker","year":"2015","unstructured":"Shuker N, van Gelder T, Hesselink DA (2015) Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical management. Transplant Rev 29(2):78\u201384","journal-title":"Transplant Rev"},{"issue":"3","key":"2725_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1208\/s12248-014-9577-8","volume":"16","author":"C G\u00e9rard","year":"2014","unstructured":"G\u00e9rard C, Stocco J, Hulin A, Blanchet B, Verstuyft C, Durand F, Conti F, Duvoux C, Tod M (2014) Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J 16(3):379\u2013391","journal-title":"AAPS J"},{"issue":"1","key":"2725_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","volume":"6","author":"Andreas H. Groll","year":"2016","unstructured":"Groll AH, Desai A, Han D, et al. (2017) Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev :n\/a-n\/a 6(1):76\u201385","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"11","key":"2725_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2165\/00003088-200746110-00002","volume":"46","author":"E Teicher","year":"2007","unstructured":"Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, Duclos-Vall\u00e9e JC, Taburet AM, Samuel D, Vittecoq D (2007) Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 46(11):941\u2013952","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"2725_CR13","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1111\/j.1600-6143.2007.02007.x","volume":"7","author":"LA Frassetto","year":"2007","unstructured":"Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, Carlson L, Benet LZ (2007) Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 7(12):2816\u20132820","journal-title":"Am J Transplant"},{"issue":"3","key":"2725_CR14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bcp.12703","volume":"80","author":"H de Jonge","year":"2015","unstructured":"de Jonge H, Vanhove T, de Loor H, Verbeke K, Kuypers DRJ (2015) Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol 80(3):548\u2013559","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2725_CR15","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.transproceed.2015.12.096","volume":"48","author":"S Limsrichamrern","year":"2016","unstructured":"Limsrichamrern S, Chanapul C, Mahawithitwong P, Sirivatanauksorn Y, Kositamongkol P, Asavakarn S, Tovikkai C, Dumronggittigule W (2016) Correlation of hematocrit and tacrolimus level in liver transplant recipients. Transplant Proc 48(4):1176\u20131178","journal-title":"Transplant Proc"},{"issue":"4","key":"2725_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1365-2125.2011.04116.x","volume":"73","author":"AJ Wilhelm","year":"2012","unstructured":"Wilhelm AJ, de Graaf P, Veldkamp AI, Janssen JJWM, Huijgens PC, Swart EL (2012) Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. Br J Clin Pharmacol 73(4):553\u2013563","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2725_CR17","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/jac\/dkv122","volume":"70","author":"JE Rower","year":"2015","unstructured":"Rower JE, Meissner EG, Jimmerson LC, Osinusi A, Sims Z, Petersen T, Bushman LR, Wolfe P, McHutchison JG, Kottilil S, Kiser JJ (2015) Serum and cellular ribavirin pharmacokinetic and concentration\u2013effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother 70(8):2322\u20132329","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2725_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/tri.12653","volume":"29","author":"Y Ueda","year":"2016","unstructured":"Ueda Y, Uemoto S (2016) Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation. Transpl Int 29(1):119\u2013121","journal-title":"Transpl Int"},{"key":"2725_CR19","unstructured":"FDA. Sofosbuvir clinical pharmacology and biopharmaceutics reviews.2013"},{"key":"2725_CR20","unstructured":"FDA. Daclatasvir clinical pharmacology and biopharmacuetics reviews.2015"},{"issue":"4","key":"2725_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/jvh.12645","volume":"24","author":"E Lawitz","year":"2017","unstructured":"Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, Vandevoorde A, van Remoortere P, Jacquemyn B, Luo D, Ouwerkerk-Mahadevan S, Vijgen L, van Eygen V, Beumont M (2017) Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat 24(4):287\u2013294","journal-title":"J Viral Hepat"},{"issue":"5","key":"2725_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40261-015-0279-5","volume":"35","author":"M Bifano","year":"2015","unstructured":"Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ (2015) An open-label investigation into drug\u2013drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig 35(5):281\u2013289","journal-title":"Clin Drug Investig"},{"issue":"4","key":"2725_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/lt.24416","volume":"22","author":"RJ Fontana","year":"2016","unstructured":"Fontana RJ, Brown RS, Moreno-Zamora A et al (2016) Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 22(4):446\u2013458","journal-title":"Liver Transpl"},{"issue":"5","key":"2725_CR24","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/hep.28446","volume":"63","author":"F Poordad","year":"2016","unstructured":"Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES (2016) Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 63(5):1493\u20131505","journal-title":"Hepatology."}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02725-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02725-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02725-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T23:14:28Z","timestamp":1596496468000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02725-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2725"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02725-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol has been implemented in accordance with the Declaration of Helsinki and French laws on biomedical research and was approved by the \u201cSouth Mediterranean Ethics Committee\u201d (France).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Didier Samuel has been a clinical investigator, speaker and\/or consultant for Astellas, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Abbvie, Novartis, Merck Sharp & Dohme and Roche. Georges-Philippe Pageaux has been a clinical investigator, speaker and\/or consultant for Astellas, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp & Dohme, Novartis and Roche. Jean-Charles Duclos-Vall\u00e9e has been a clinical investigator, speaker and\/or consultant for Astellas, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Abbvie, Novartis and Roche. Audrey Coilly has been a clinical investigator, speaker and\/or consultant for Astellas, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Novartis, Merck Sharp & Dohme and Abbvie. Christophe Moreno was paid as speaker or adviser from MSD, Janssen, Bristol-Myers Squibb, Abbvie and Gilead. He received research Grant from Abbvie, Janssen, Astellas, Gilead Sciences and Roche pharmaceutical companies. Victor de Ledinghen has been a clinical investigator, speaker and\/or consultant for Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Abbvie, Merck Sharp & Dohme and Roche. Aur\u00e9lie Barrail-Tran has been a speaker for Gilead Sciences. Anne-Marie Taburet received travel fees to attend meetings from Gilead, BMS and Janssen. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}